Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Global Blood Therapeutics, Inc. (GBT)

67.99   0.02 (0.03%) 09-24 15:11
Open: 67.91 Pre. Close: 67.97
High: 68.04 Low: 67.83
Volume: 1,425,027 Market Cap: 4,588(M)
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 68.1 - 68.37 68.37 - 68.67
Low: 67.1 - 67.39 67.39 - 67.72
Close: 67.46 - 67.92 67.92 - 68.44

Technical analysis

as of: 2022-09-23 4:24:24 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 79.65     One year: 93.04
Support: Support1: 67.4    Support2: 66.91
Resistance: Resistance1: 68.19    Resistance2: 79.65
Pivot: 67.86
Moving Average: MA(5): 67.91     MA(20): 67.84
MA(100): 42.72     MA(250): 35.72
MACD: MACD(12,26): 2.3     Signal(9): 3.1
Stochastic oscillator: %K(14,3): 51.6     %D(3): 51.6
RSI: RSI(14): 77.9
52-week: High: 73.01  Low: 21.64
Average Vol(K): 3-Month: 3,432 (K)  10-Days: 2,727 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ GBT ] has closed below upper band by 23.7%. Bollinger Bands are 96.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 24 Sep 2022
STOCKHOLDER ALERT: The M&A Class Action Firm Launches Merger Inquiry - RFP, SBTX, GBT, EVOP - EVO Paymen - Benzinga

Fri, 23 Sep 2022
Does Global Blood Therapeutics Inc (GBT) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver

Thu, 22 Sep 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, RFP, GBT, SBTX - EVO Payments (NASDAQ:EVOP - Benzinga

Tue, 20 Sep 2022
GBT Backs Passage of Expansive SCD Treatment Centers Act | Sickle... - Sickle Cell Anemia News

Fri, 16 Sep 2022
GBT: Pfizer Acquisition Signals Increasing M/A Deals - Seeking Alpha

Wed, 14 Sep 2022
GBT's Automatic Correction of Integrated Circuits - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 67 (M)
Shares Float 58 (M)
% Held by Insiders 2.4 (%)
% Held by Institutions 112.1 (%)
Shares Short 9,370 (K)
Shares Short P.Month 9,850 (K)

Stock Financials

EPS -4.87
EPS Est Next Qtl -0.68
EPS Est This Year -2.45
EPS Est Next Year -2.92
Book Value (p.s.) 1.75
Profit Margin (%) -137.4
Operating Margin (%) -127.5
Return on Assets (ttm) -25.2
Return on Equity (ttm) -148.6
Qtrly Rev. Growth 50.5
Gross Profit (p.s.) 2.83
Sales Per Share 3.48
EBITDA (p.s.) -4.35
Qtrly Earnings Growth 0
Operating Cash Flow -249 (M)
Levered Free Cash Flow -135 (M)

Stock Valuations

PE Ratio -13.99
PEG Ratio -0.4
Price to Book value 38.63
Price to Sales 19.52
Price to Cash Flow -18.4

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.